Management of advanced prostate cancer in a middle-income country

real-world consideration of the Advanced Prostate Cancer Consensus Conference 2017

Marniza Saad, Adlinda Alip, Jasmine Lim, Matin Mellor Abdullah, Flora Li Tze Chong, Chong Beng Chua, Fuad Ismail, Rachael Kit Tsan Khong, Chun Sen Lim, Chit Sin Loh, Rohan Malek, Khairul Asri Mohd Ghani, Ibtisam Md Noor, Noor Ashani Md Yusoff, Noor Azam Nasuha, Azad Razack, Hwoei Fen Soo Hoo, Murali Sundram, Hui Meng Tan, Muthukkumaran Thiagarajan & 3 others Guan Chou Teh, Pei Jye Voon, Teng Aik Ong

Research output: Contribution to journalReview article

Abstract

Objective: To examine the results of the Malaysian Advanced Prostate Cancer Consensus Conference (MyAPCCC) 2018, held for assessing the generalizability of consensus reached at the Advanced Prostate Cancer Consensus Conference (APCCC 2017) to Malaysia, a middle-income country. Methods: Six key sections were chosen: (1) high-risk localized and locally advanced prostate cancer, (2) oligometastatic prostate cancer, (3) castration-naïve prostate cancer, (4) castrate resistant prostate cancer, (5) use of osteoclast-targeted therapy and (6) global access to prostate cancer drugs. There were 101 consensus questions, consisting of 91 questions from APCCC 2017 and 10 new questions from MyAPCCC 2018, selected and modified by the steering committee; of which, 23 questions were assessed in both ideal world and real-world settings. A panel of 22 experts, comprising of 11 urologists and 11 oncologists, voted on 101 predefined questions anonymously. Final voting results were compared with the APCCC 2017 outcomes. Results: Most voting results from the MyAPCCC 2018 were consistent with the APCCC 2017 outcomes. No consensus was achieved for controversial topics with little level I evidence, such as management of oligometastatic disease. No consensus was reached on using high-cost drugs in castration-naïve or castration-resistant metastatic prostate cancer in real-world settings. All panellists recommended using generic drugs when available. Conclusions: The MyAPCCC 2018 voting results reflect the management of advanced prostate cancer in a middle-income country in a real-world setting. These results may serve as a guide for local clinical practices and highlight the financial challenges in modern healthcare.

Original languageEnglish
JournalBJU International
DOIs
Publication statusPublished - 1 Jan 2019

Fingerprint

Prostatic Neoplasms
Castration
Politics
Generic Drugs
Drug Costs
Malaysia
Osteoclasts
Disease Management
Delivery of Health Care

Keywords

  • #pcsm
  • #ProstateCancer
  • castration-naïve prostate cancer
  • castration-resistant prostate cancer
  • cost and access to treatment
  • high-risk localized prostate cancer
  • low-middle income countries
  • oligometastatic prostate cancer

ASJC Scopus subject areas

  • Urology

Cite this

Management of advanced prostate cancer in a middle-income country : real-world consideration of the Advanced Prostate Cancer Consensus Conference 2017. / Saad, Marniza; Alip, Adlinda; Lim, Jasmine; Abdullah, Matin Mellor; Chong, Flora Li Tze; Chua, Chong Beng; Ismail, Fuad; Khong, Rachael Kit Tsan; Lim, Chun Sen; Loh, Chit Sin; Malek, Rohan; Mohd Ghani, Khairul Asri; Md Noor, Ibtisam; Md Yusoff, Noor Ashani; Nasuha, Noor Azam; Razack, Azad; Soo Hoo, Hwoei Fen; Sundram, Murali; Tan, Hui Meng; Thiagarajan, Muthukkumaran; Teh, Guan Chou; Voon, Pei Jye; Ong, Teng Aik.

In: BJU International, 01.01.2019.

Research output: Contribution to journalReview article

Saad, M, Alip, A, Lim, J, Abdullah, MM, Chong, FLT, Chua, CB, Ismail, F, Khong, RKT, Lim, CS, Loh, CS, Malek, R, Mohd Ghani, KA, Md Noor, I, Md Yusoff, NA, Nasuha, NA, Razack, A, Soo Hoo, HF, Sundram, M, Tan, HM, Thiagarajan, M, Teh, GC, Voon, PJ & Ong, TA 2019, 'Management of advanced prostate cancer in a middle-income country: real-world consideration of the Advanced Prostate Cancer Consensus Conference 2017', BJU International. https://doi.org/10.1111/bju.14807
Saad, Marniza ; Alip, Adlinda ; Lim, Jasmine ; Abdullah, Matin Mellor ; Chong, Flora Li Tze ; Chua, Chong Beng ; Ismail, Fuad ; Khong, Rachael Kit Tsan ; Lim, Chun Sen ; Loh, Chit Sin ; Malek, Rohan ; Mohd Ghani, Khairul Asri ; Md Noor, Ibtisam ; Md Yusoff, Noor Ashani ; Nasuha, Noor Azam ; Razack, Azad ; Soo Hoo, Hwoei Fen ; Sundram, Murali ; Tan, Hui Meng ; Thiagarajan, Muthukkumaran ; Teh, Guan Chou ; Voon, Pei Jye ; Ong, Teng Aik. / Management of advanced prostate cancer in a middle-income country : real-world consideration of the Advanced Prostate Cancer Consensus Conference 2017. In: BJU International. 2019.
@article{25e9f6ac759344f7be1e1eac83b2c7e4,
title = "Management of advanced prostate cancer in a middle-income country: real-world consideration of the Advanced Prostate Cancer Consensus Conference 2017",
abstract = "Objective: To examine the results of the Malaysian Advanced Prostate Cancer Consensus Conference (MyAPCCC) 2018, held for assessing the generalizability of consensus reached at the Advanced Prostate Cancer Consensus Conference (APCCC 2017) to Malaysia, a middle-income country. Methods: Six key sections were chosen: (1) high-risk localized and locally advanced prostate cancer, (2) oligometastatic prostate cancer, (3) castration-na{\"i}ve prostate cancer, (4) castrate resistant prostate cancer, (5) use of osteoclast-targeted therapy and (6) global access to prostate cancer drugs. There were 101 consensus questions, consisting of 91 questions from APCCC 2017 and 10 new questions from MyAPCCC 2018, selected and modified by the steering committee; of which, 23 questions were assessed in both ideal world and real-world settings. A panel of 22 experts, comprising of 11 urologists and 11 oncologists, voted on 101 predefined questions anonymously. Final voting results were compared with the APCCC 2017 outcomes. Results: Most voting results from the MyAPCCC 2018 were consistent with the APCCC 2017 outcomes. No consensus was achieved for controversial topics with little level I evidence, such as management of oligometastatic disease. No consensus was reached on using high-cost drugs in castration-na{\"i}ve or castration-resistant metastatic prostate cancer in real-world settings. All panellists recommended using generic drugs when available. Conclusions: The MyAPCCC 2018 voting results reflect the management of advanced prostate cancer in a middle-income country in a real-world setting. These results may serve as a guide for local clinical practices and highlight the financial challenges in modern healthcare.",
keywords = "#pcsm, #ProstateCancer, castration-na{\"i}ve prostate cancer, castration-resistant prostate cancer, cost and access to treatment, high-risk localized prostate cancer, low-middle income countries, oligometastatic prostate cancer",
author = "Marniza Saad and Adlinda Alip and Jasmine Lim and Abdullah, {Matin Mellor} and Chong, {Flora Li Tze} and Chua, {Chong Beng} and Fuad Ismail and Khong, {Rachael Kit Tsan} and Lim, {Chun Sen} and Loh, {Chit Sin} and Rohan Malek and {Mohd Ghani}, {Khairul Asri} and {Md Noor}, Ibtisam and {Md Yusoff}, {Noor Ashani} and Nasuha, {Noor Azam} and Azad Razack and {Soo Hoo}, {Hwoei Fen} and Murali Sundram and Tan, {Hui Meng} and Muthukkumaran Thiagarajan and Teh, {Guan Chou} and Voon, {Pei Jye} and Ong, {Teng Aik}",
year = "2019",
month = "1",
day = "1",
doi = "10.1111/bju.14807",
language = "English",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Management of advanced prostate cancer in a middle-income country

T2 - real-world consideration of the Advanced Prostate Cancer Consensus Conference 2017

AU - Saad, Marniza

AU - Alip, Adlinda

AU - Lim, Jasmine

AU - Abdullah, Matin Mellor

AU - Chong, Flora Li Tze

AU - Chua, Chong Beng

AU - Ismail, Fuad

AU - Khong, Rachael Kit Tsan

AU - Lim, Chun Sen

AU - Loh, Chit Sin

AU - Malek, Rohan

AU - Mohd Ghani, Khairul Asri

AU - Md Noor, Ibtisam

AU - Md Yusoff, Noor Ashani

AU - Nasuha, Noor Azam

AU - Razack, Azad

AU - Soo Hoo, Hwoei Fen

AU - Sundram, Murali

AU - Tan, Hui Meng

AU - Thiagarajan, Muthukkumaran

AU - Teh, Guan Chou

AU - Voon, Pei Jye

AU - Ong, Teng Aik

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Objective: To examine the results of the Malaysian Advanced Prostate Cancer Consensus Conference (MyAPCCC) 2018, held for assessing the generalizability of consensus reached at the Advanced Prostate Cancer Consensus Conference (APCCC 2017) to Malaysia, a middle-income country. Methods: Six key sections were chosen: (1) high-risk localized and locally advanced prostate cancer, (2) oligometastatic prostate cancer, (3) castration-naïve prostate cancer, (4) castrate resistant prostate cancer, (5) use of osteoclast-targeted therapy and (6) global access to prostate cancer drugs. There were 101 consensus questions, consisting of 91 questions from APCCC 2017 and 10 new questions from MyAPCCC 2018, selected and modified by the steering committee; of which, 23 questions were assessed in both ideal world and real-world settings. A panel of 22 experts, comprising of 11 urologists and 11 oncologists, voted on 101 predefined questions anonymously. Final voting results were compared with the APCCC 2017 outcomes. Results: Most voting results from the MyAPCCC 2018 were consistent with the APCCC 2017 outcomes. No consensus was achieved for controversial topics with little level I evidence, such as management of oligometastatic disease. No consensus was reached on using high-cost drugs in castration-naïve or castration-resistant metastatic prostate cancer in real-world settings. All panellists recommended using generic drugs when available. Conclusions: The MyAPCCC 2018 voting results reflect the management of advanced prostate cancer in a middle-income country in a real-world setting. These results may serve as a guide for local clinical practices and highlight the financial challenges in modern healthcare.

AB - Objective: To examine the results of the Malaysian Advanced Prostate Cancer Consensus Conference (MyAPCCC) 2018, held for assessing the generalizability of consensus reached at the Advanced Prostate Cancer Consensus Conference (APCCC 2017) to Malaysia, a middle-income country. Methods: Six key sections were chosen: (1) high-risk localized and locally advanced prostate cancer, (2) oligometastatic prostate cancer, (3) castration-naïve prostate cancer, (4) castrate resistant prostate cancer, (5) use of osteoclast-targeted therapy and (6) global access to prostate cancer drugs. There were 101 consensus questions, consisting of 91 questions from APCCC 2017 and 10 new questions from MyAPCCC 2018, selected and modified by the steering committee; of which, 23 questions were assessed in both ideal world and real-world settings. A panel of 22 experts, comprising of 11 urologists and 11 oncologists, voted on 101 predefined questions anonymously. Final voting results were compared with the APCCC 2017 outcomes. Results: Most voting results from the MyAPCCC 2018 were consistent with the APCCC 2017 outcomes. No consensus was achieved for controversial topics with little level I evidence, such as management of oligometastatic disease. No consensus was reached on using high-cost drugs in castration-naïve or castration-resistant metastatic prostate cancer in real-world settings. All panellists recommended using generic drugs when available. Conclusions: The MyAPCCC 2018 voting results reflect the management of advanced prostate cancer in a middle-income country in a real-world setting. These results may serve as a guide for local clinical practices and highlight the financial challenges in modern healthcare.

KW - #pcsm

KW - #ProstateCancer

KW - castration-naïve prostate cancer

KW - castration-resistant prostate cancer

KW - cost and access to treatment

KW - high-risk localized prostate cancer

KW - low-middle income countries

KW - oligometastatic prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=85067671578&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067671578&partnerID=8YFLogxK

U2 - 10.1111/bju.14807

DO - 10.1111/bju.14807

M3 - Review article

JO - BJU International

JF - BJU International

SN - 1464-4096

ER -